Tremfya vs SKYRIZI
Side-by-side comparison of Tremfya and SKYRIZI — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Tremfya | SKYRIZI |
|---|
| Generic name | GUSELKUMAB | SKYRIZI |
|---|
| Sponsor | Johnson & Johnson | Chong Kun Dang Pharmaceutical |
|---|
| Drug class | Interleukin-23 Antagonist [EPC] | IL-23 inhibitor monoclonal antibody |
|---|
| Molecular target | p19 subunit of IL-23 | IL-23 (p19 subunit) |
|---|
| Modality | Monoclonal antibody | Biologic |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Immunology | Immunology/Dermatology |
|---|
| First approval | 2017 | — |
|---|
Mechanism of action
| Tremfya | Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release. |
|---|
| SKYRIZI | SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. |
|---|
Approved indications
Tremfya
- Palmoplantar pustulosis
- Plaque psoriasis
SKYRIZI
- Moderate to severe plaque psoriasis
- Crohn's disease
- Ulcerative colitis
Common side effects
Tremfya
- Upper respiratory infections
- Injection site reactions
- Headache
- Arthralgia
- Diarrhea
- Gastroenteritis
- Tinea infections
- Herpes simplex infections
SKYRIZI
- Upper respiratory tract infection
- Injection site reactions
- Headache
- Fatigue
Further reading